Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab Vedotin in Metastatic Squamous Cell Carcinoma of the Penis
NCT06104618Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Dec 2023
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin in squamous cell carcinoma of the penis, sponsored by Mayo Clinic. Started Dec 2023; status: recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
squamous cell carcinoma of the penis
Beyond the preview
Go deeper on NCT06104618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06104618.